RNA interference as potential therapy for neurodegenerative disease: Applications to inclusion-body myositis?

Neurology

Volumn 66, Issue 2 SUPPL. 1, 2006, Pages

  Paulson, Henry ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b SIRNA Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA; MESSENGER RNA; MICRORNA; SMALL INTERFERING RNA;

CONFERENCE PAPER; DEGENERATIVE DISEASE; GENE SILENCING; GENE TARGETING; HUMAN; INCLUSION BODY MYOSITIS; NEUROLOGIC DISEASE; NEUROMODULATION; NEUROPATHOLOGY; PRIORITY JOURNAL; RNA INTERFERENCE; SEQUENCE HOMOLOGY; TRANSGENIC MOUSE; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; GENE THERAPY; GENETICS; METHODOLOGY; MOUSE; REVIEW; SPINOCEREBELLAR DEGENERATION;

ANIMALS; DISEASE MODELS, ANIMAL; GENE TARGETING; GENE THERAPY; HUMANS; MICE; MICE, TRANSGENIC; MICRORNAS; MYOSITIS, INCLUSION BODY; RNA; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SPINOCEREBELLAR ATAXIAS;

EID: 33644868945     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000192310.07041.53     Document Type: Conference Paper

References (32)

1. Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol 2004;17:561-567.
2. Askanas V, Engel WK. Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-beta, misfolded proteins, predisposing genes, and aging. Curr Opin Rheumatol 2003;15:737-744.
3. Eisenberg I, Avidan N, Potikha T, et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet 2001;29:83-87.
4. Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004;36:377-381.
5. Davidson B, Paulson H. Molecular medicine for the brain: silencing of disease genes with RNA interference. Lancet Neurol 2004;3:145-149.
6. Stevenson M. Therapeutic potential of RNA interference. N Engl J Med 2004;351:1772-1777.
7. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004;431:371-378.
8. Mello CC, Conte D Jr. Revealing the world of RNA interference. Nature 2004;431:338-42.
9. Tomari Y, Zamore PD. Perspective: machines for RNAi. Genes Dev 2005;19:517-29.
10. Kanellopoulou C, Muljo SA, Kung AL, et al. Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev 2005;19:489-501.
11. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005;433:769-773.
12. Jin P, Alisch RS, Warren ST. RNA and microRNAs in fragile X mental retardation. Nat Cell Biol 2004;6:1048-1053.
13. Couzin J. Breakthrough of the year. Small RNAs make big splash. Science 2002;298:2296-2297.
14. Miller VM, Xia H, Marrs GL, et al. Allele Specific Silencing of Dominant Disease Genes. Proc Natl Acad Sci U S A 2003;100:7195-7200.
15. Miller V, Gouvion C, Davidson B, Paulson H. Targeting Alzheimer's disease genes with RNA interference: An efficient strategy for silencing mutant allele. Nucleic Acids Res 2004;32:661-668.
16. Ding H, Schwarz DS, Keene A, et al. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell 2003;2:209-217.
17. Maxwell MM, Pasinelli P, Kazantsev AG, Brown RH Jr. RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells. Proc Natl Acad Sci U S A 2004;101:3178-3183.
18. Abdelgany A, Wood M, Beeson D. Allele-specific silencing of a pathogenic mutant acetylcholine receptor subunit by RNA interference. Hum Mol Genet 2003;12:2637-2644.
19. Xia H, Mao Q, Eliason S, et al. RNAi suppression of neurodegeneration in a mouse model of SCA1. Nat Med 2004;10:816-820.
20. Ross CA , Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med 2004;10 Suppl:S10-S17.
21. Li SH, Li XJ. Huntingtin and its role in neuronal degeneration. Neuroscientist 2004;10:467-475.
22. Xia XG, Zhou H, Zhou S, Yu Y, Wu R, Xu Z. An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu, Zn superoxide dismutase. J Neurochem 2005;92:362-367.
23. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432:173-178.
24. Davidson TJ, Harel S, Arboleda VA, et al. Highly efficient small interfering RNA delivery to primary mammalian neurons induces MicroRNA-like effects before mRNA degradation. J Neurosci 2004;24:10040-10046.
25. Ferrer I, Martin B, Castano JG, Lucas JJ, Moreno D, Olive M. Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J Neuropathol Exp Neurol 2004;63:484-498.
26. Vattemi G, Engel WK, McFerrin J, Askanas V. Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. Am J Pathol 2004;164:1-7.
27. Sugarman MC, Yamasaki TR, Oddo S, et al. Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci U S A 2002;99:6334-6339.
28. Gregorevic P, Blankinship MJ, Chamberlain JS. Viral vectors for gene transfer to striated muscle. Curr Opin Mol Ther 2004;6:491-498.
29. Wells DJ. Opening the floodgates: clinically applicable hydrodynamic delivery of plasmid DNA to skeletal muscle. Mol Ther 2004;10:207-208.
30. Harper SQ, Staber PD, He X, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 2005;102:5820-5825.
31. Ralph GS, Radcliffe PA, Day DM, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 2005;11:429-433.
32. Raoul C, Abbas-Terki T, Bensadoun JC, et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005;11:423-428.